To our knowledge, the present study is the first to investigate the impacts of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of Japanese patients with lung adenocarcinoma treated with ICIs using the C-CAT database. This evidence concerns the gene TP53 and lung adenocarcinoma.